{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T05:59:56Z","timestamp":1785477596502,"version":"3.56.0"},"reference-count":65,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100015442","name":"Global Brain Health Institute","doi-asserted-by":"publisher","award":["212322"],"award-info":[{"award-number":["212322"]}],"id":[{"id":"10.13039\/100015442","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Alzheimer's &amp;amp; Dementia"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>INTRODUCTION<\/jats:title>\n                    <jats:p>Countries have varying, limited healthcare budgets for emerging disease\u2010modifying therapies. Cost\u2010effectiveness analysis, combined with country\u2010level cost\u2010effectiveness thresholds, can be used to estimate value\u2010based prices (VBPs) for lecanemab and donanemab across 174 countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>The cost\u2010effectiveness of lecanemab and donanemab was estimated using incremental cost and quality\u2010adjusted life years (QALYs) compared to usual care. Published cost\u2010effectiveness thresholds were used to estimate VBPs of these drugs across 174 countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Compared to usual care, lecanemab and donanemab respectively increased average QALYs by 0.38 and 0.51. By country income status, VBPs for lecanemab and donanemab respectively ranged between $254 to $9434 and $387 to $13,964 (high income), $90 to $1025 and $137 to $1507 (upper middle income), $11 to $623 and $21 to $956 (lower middle income) and $4 to $18 and $9 to $32 (low income).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSSION<\/jats:title>\n                    <jats:p>VBPs indicate how much 174 countries should be willing to pay. This framework can also be adapted and refined in the negotiation of country pricing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/alz.71308","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T11:00:25Z","timestamp":1778670025000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Value\u2010based prices of emerging disease\u2010modifying therapies for Alzheimer's disease in 174 countries: a cost\u2010effectiveness and threshold analysis"],"prefix":"10.1002","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8187-8277","authenticated-orcid":false,"given":"Men Thi","family":"Hoang","sequence":"first","affiliation":[{"name":"School of Medicine Trinity College Dublin  Dublin Leinster Ireland"},{"name":"Faculty of Business Administration Van Lang University  Ho Chi Minh City Vietnam"},{"name":"Manchester Centre for Health Economics Division of Population Health Health Services Research and Primary Care University of Manchester, Greater Manchester  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G.","family":"Kahn","sequence":"additional","affiliation":[{"name":"Global Brain Health Institute University of California  San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8649-0773","authenticated-orcid":false,"given":"Sanjib","family":"Saha","sequence":"additional","affiliation":[{"name":"Health Economics Unit Lund University, Scania  Lund Sweden"},{"name":"Global Brain Health Institute Trinity College Dublin  Dublin Leinster Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1421-2966","authenticated-orcid":false,"given":"Dominic","family":"Tr\u00e9pel","sequence":"additional","affiliation":[{"name":"School of Medicine Trinity College Dublin  Dublin Leinster Ireland"},{"name":"Global Brain Health Institute Trinity College Dublin  Dublin Leinster Ireland"},{"name":"Trinity College Institute of Neuroscience Trinity College Dublin  Dublin Leinster Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266\u2010017\u20100499\u2010x"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.11.115"},{"key":"e_1_2_9_4_1","unstructured":"National Institute for Health and Care Excellence.Dementia: assessment management and support for people living with dementia and their carers.2018.https:\/\/www.nice.org.uk\/guidance\/ng97\/chapter\/Update\u2010information"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2212948"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100708"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12213"},{"key":"e_1_2_9_9_1","unstructured":"BrooksM.Biogen's abandonment of controversial Alzheimer's drug is no surprise experts say. Accessed 01 March 2024.https:\/\/www.medscape.com\/viewarticle\/biogens\u2010abandonment\u2010controversial\u2010alzheimers\u2010drug\u2010no\u20102024a10002aq?form=fpf"},{"key":"e_1_2_9_10_1","unstructured":"ChaM Yu F.Pharma's first\u2010to\u2010market advantage. Accessed 20 Oct 2024.https:\/\/www.mckinsey.com\/industries\/life\u2010sciences\/our\u2010insights\/pharmas\u2010first\u2010to\u2010market\u2010advantage"},{"key":"e_1_2_9_11_1","unstructured":"Kyodo News.Eisai\u2010Biogen Alzheimer's therapy to cost 2.98 million yen per year. Accessed 01 Sep 2024.https:\/\/english.kyodonews.net\/news\/2023\/12\/0bf5503667de\u2010eisai\u2010biogen\u2010alzheimers\u2010therapy\u2010to\u2010cost\u2010298\u2010mil\u2010yen\u2010per\u2010year.html"},{"key":"e_1_2_9_12_1","unstructured":"Eisai Co Ltd.Leqembi\u00ae (lecanemab) is the first medicine that slows progression of early Alzheimer's disease to be authorized in the European Union. Accessed 29 May 2025.https:\/\/www.eisai.com\/news\/2024\/news202460.html"},{"key":"e_1_2_9_13_1","unstructured":"Alzheimer's Association.Donanemab approved for treatment of early Alzheimer's disease. Accessed 05 July 2024.https:\/\/www.alz.org\/alzheimers\u2010dementia\/treatments\/donanemab#:~:text=In%20a%20news%20release%2C%20the were%20cleared%20from%20the%20brain"},{"key":"e_1_2_9_14_1","unstructured":"Eli Lilly and Company.Lilly's Kisunla (donanemab) receives marketing authorization in Australia for the treatment of early symptomatic Alzheimer's disease. Accessed 25 May 2025.https:\/\/investor.lilly.com\/news\u2010releases\/news\u2010release\u2010details\/lillys\u2010kisunla\u2010donanemab\u2010receives\u2010marketing\u2010authorization?utm_source=chatgpt.com"},{"key":"e_1_2_9_15_1","unstructured":"ISPOR\u2013The Professional Society for Health Economics and Outcomes Research.Pharmacoeconomic guidelines around the world. Accessed 20 Oct 2024.https:\/\/www.ispor.org\/heor\u2010resources\/more\u2010heor\u2010resources\/pharmacoeconomic\u2010guidelines"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000012452"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.3854"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcad175"},{"key":"e_1_2_9_19_1","unstructured":"European Medicines Agency.Leqembi. Accessed 01 Aug 2024.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/leqembi"},{"key":"e_1_2_9_20_1","unstructured":"National Institute for Health and Care Excellence (NICE).Benefits of new Alzheimer's treatment lecanemab are too small to justify the cost to the NHS. Accessed 25 August 2024.https:\/\/www.nice.org.uk\/news\/articles\/benefits\u2010of\u2010new\u2010alzheimer\u2010s\u2010treatment\u2010lecanemab\u2010are\u2010too\u2010small\u2010to\u2010justify\u2010the\u2010cost\u2010to\u2010the\u2010nhs"},{"key":"e_1_2_9_21_1","unstructured":"National Institute for Health and Care Excellence.New Alzheimer's treatment donanemab does not currently demonstrate value for the NHS says NICE. Accessed 23 Oct 2024.https:\/\/www.nice.org.uk\/news\/articles\/new\u2010alzheimer\u2010s\u2010treatment\u2010donanemab\u2010does\u2010not\u2010currently\u2010demonstrate\u2010value\u2010for\u2010the\u2010nhs\u2010says\u2010nice?utm_medium=organic&utm_source=linkedin&utm_campaign=donanemab&utm_content=graphic"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39434.500185.25"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101337"},{"key":"e_1_2_9_24_1","volume-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond MF","year":"2015"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000013314"},{"key":"e_1_2_9_26_1","unstructured":"The World Bank.World Health Organization Global Health Expenditure database.https:\/\/data.worldbank.org\/indicator\/SH.XPD.CHEX.PC.CD?end=2021&start=2021&view=map"},{"key":"e_1_2_9_27_1","unstructured":"Social Security Administration.Actuarial Life Table. Accessed 01\/01 2021.https:\/\/www.ssa.gov\/oact\/STATS\/table4c6.html"},{"key":"e_1_2_9_28_1","unstructured":"World Health Organization.The global health observatory: Life tables by country (GHE: Life tables).https:\/\/apps.who.int\/gho\/\/data\/node.main.LIFECOUNTRY?lang=en"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214\u2010109X(23)00162\u20106"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120\u2010021\u201000272\u20101"},{"key":"e_1_2_9_31_1","unstructured":"JohnsonRW.What is the lifetime risk of needing and receiving long\u2010term services and supports? Accessed 01 January 2024.https:\/\/aspe.hhs.gov\/reports\/what\u2010lifetime\u2010risk\u2010needing\u2010receiving\u2010long\u2010term\u2010services\u2010supports\u20100"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883\u2010023\u201003353\u2010w"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.52.6.1138"},{"key":"e_1_2_9_34_1","unstructured":"LinG WhittingtonM WrightA et\u00a0al.ICER publishes final evidence report on lecanemab for Alzheimer's disease.2023.https:\/\/icer.org\/news\u2010insights\/press\u2010releases\/icer\u2010publishes\u2010final\u2010evidence\u2010report\u2010on\u2010lecanemab\u2010for\u2010alzheimers\u2010disease\/"},{"key":"e_1_2_9_35_1","unstructured":"U.S. Bureau of Labor Statistics.Consumer price index for all urban consumers (CPI\u2010U): medical care. Accessed 30 Apr 2024.https:\/\/data.bls.gov\/timeseries\/CUUR0000SAM?output_view=data"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100657"},{"key":"e_1_2_9_37_1","unstructured":"Centers for Medicare & Medicaid Services.Physician Fee Schedule.https:\/\/www.cms.gov\/medicare\/physician\u2010fee\u2010schedule\/search"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120\u2010022\u201000373\u20105"},{"key":"e_1_2_9_39_1","unstructured":"IBM. IBM Micromedex\u00ae RED BOOK. Accessed 30 Apr 2024.https:\/\/www.ibm.com\/products\/micromedex\u2010red\u2010book"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2015.01.007"},{"key":"e_1_2_9_41_1","unstructured":"Drugs.com.Donepezil prices coupons and patient assistance programs. Accessed 30 Apr 2024.https:\/\/www.drugs.com\/price\u2010guide\/donepezil"},{"key":"e_1_2_9_42_1","unstructured":"Drugs.com.Memantine prices coupons and patient assistance programs. Accessed 30 Apr 2024.https:\/\/www.drugs.com\/price\u2010guide\/memantine"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.3233\/jad\u2010200133"},{"key":"e_1_2_9_44_1","unstructured":"Genworth.Cost of care survey. Accessed 15 May 2024.https:\/\/www.genworth.com\/aging\u2010and\u2010you\/finances\/cost\u2010of\u2010care"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2017.09.005"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195\u2010020\u201000723\u20101"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD\u2010191212"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12603\u2010014\u20100500\u2010x"},{"key":"e_1_2_9_49_1","unstructured":"World Health Organization.Global status report on the public health response to dementia.2021:61.https:\/\/www.who.int\/publications\/i\/item\/9789240033245"},{"key":"e_1_2_9_50_1","unstructured":"U.S. Bureau of Labor Statistics.Average hourly and weekly earnings of all employees on private nonfarm payrolls by industry sector seasonally adjusted. Accessed 30 Apr 2024.https:\/\/www.bls.gov\/news.release\/empsit.t19.htm"},{"key":"e_1_2_9_51_1","unstructured":"International Labour Organization.Average hourly earnings of employees by sex and occupation. Accessed 01 June 2024.https:\/\/rshiny.ilo.org\/dataexplorer2\/?lang=en&id=EAR_4HRL_SEX_OCU_CUR_NB_A"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136\u2010020\u201002650\u2010y"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000209218"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120\u2010023\u201000460\u20101"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.0315"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120\u2010023\u201000492\u20107"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120\u2010024\u201000649\u2010y"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2018.1524296"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/hec.3021"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12901"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2055\u20106640(20)30871\u20102"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214\u2010109X(15)00156\u20104"},{"key":"e_1_2_9_63_1","unstructured":"Eisai Co. L.Update on regulatory review of lecanemab for early Alzheimer's disease in the European Union. Accessed 01 Aug 2024.https:\/\/www.eisai.com\/news\/2024\/news202455.html"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41586\u2010023\u201002464\u20101"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X15583266"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.70151"}],"container-title":["Alzheimer's &amp; Dementia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alz.71308","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/alz.71308","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alz.71308","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T05:27:21Z","timestamp":1785475641000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1002\/alz.71308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":65,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1002\/alz.71308"],"URL":"https:\/\/doi.org\/10.1002\/alz.71308","archive":["Portico"],"relation":{},"ISSN":["1552-5260","1552-5279"],"issn-type":[{"value":"1552-5260","type":"print"},{"value":"1552-5279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"2025-12-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71308"}}